Earnings calls

Sun Pharma.Inds. concall ledger

Every earnings call for SUNPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.

SUNPHARMA · 6 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 27 Apr 2026Call held 27 Apr 2026

SUNPHARMA Q4 FY26 Earnings Call Transcript & Analysis

Combined Revenue12.4 billionOrganon EBITDA Margin30%Combined Free Cash Flow2 billionNet Debt to EBITDA2.3 xOrganon Gross Debt8.5 billion

Combined Revenue 12.4 billion; Organon EBITDA Margin 30.0%; Combined Free Cash Flow 2.0 billion. Acquisition of Organon for an equity value of $3.99 billion and enterprise value of $11.75 billion.

Read full transcript & analysis

Q3 FY26Published 31 Jan 2026Call held 31 Jan 2026

SUNPHARMA Q3 FY26 Earnings Call Transcript & Analysis

Consolidated sales for Q3 FY26 reached ₹1,54,691 million, marking a 15.1% year-on-year growth.

Read full transcript & analysis

Q2 FY26Published 11 Nov 2025Call held 11 Nov 2025

SUNPHARMA Q2 FY26 Earnings Call Transcript & Analysis

Q2 FY26 sales at INR144,052 million, recording an 8.6% growth year-on-year.

Read full transcript & analysis

Q1 FY26Published 06 Aug 2025Call held 06 Aug 2025

SUNPHARMA Q1 FY26 Earnings Call Transcript & Analysis

Consolidated sales stood at Rs. 1,37,861 million, registering a growth of 10.1% over the last year.

Read full transcript & analysis

Q4 FY25Published 29 May 2025Call held 29 May 2025

SUNPHARMA Q4 FY25 Earnings Call Transcript & Analysis

Full year FY25 sales reached Rs. 520,412 million, a growth of 9% over last year.

Read full transcript & analysis

Q3 FY25Published 06 Feb 2025Call held 06 Feb 2025

SUNPHARMA Q3 FY25 Earnings Call Transcript & Analysis

Consolidated sales for Q3 FY25 were INR134,369 million, an increase of 10.5% versus Q3 FY24.

Read full transcript & analysis